Humacyte, Inc.

Humacyte, Inc. (Nasdaq: HUMA) is a regenerative medicine company that entered public markets in 2021 through its business combination with Alpha Healthcare Acquisition Corp. (AHAC), a blank-check vehicle sponsored by Alpha Healthcare Capital that completed its IPO in 2020. The company focuses on developing and commercializing bioengineered human acellular vessels intended for vascular reconstruction and surgical repair, placing it squarely within the healthcare and biotechnology sector. Humacyte filed an 8-K with the Securities and Exchange Commission on June 9, 2026, maintaining its standard disclosure cadence as an active public reporting company. For complete filing history, SPAC deal data, and ongoing company updates on HUMA, sign up for full access at SpacDesk.